Rosen D R, Kaiser A M
Department of Colorectal Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Colorectal Dis. 2016 May;18(5):488-95. doi: 10.1111/codi.13120.
The treatment of transsphincteric anal fistula requires a balance between eradication of the disease and preservation of faecal control. A cutting seton is an old tool that is now out of vogue for many surgeons. We hypothesized that the concept remains reliable and safe with results that exceed those reported for many of the more recently described methods.
A retrospective review was conducted of real-time electronic health records (single institution, single surgeon) of patients presenting during the 14 years between 2001 and 2014 with a transsphincteric anal fistula who were treated with a cutting seton. Excluded were patients with Crohn's disease, fistulae related to malignancy or a previous anastomosis and patients whose fistula was treated by another method including a loose draining seton. Data collection included demographics, duration of the disease, duration of the treatment, outcome and continence.
In all, 121 patients (80 men) of mean age 40.2 ± 12.2 years (range 18-76) with a mean follow-up of 5.1 ± 3.3 (1-24) months were included in the analysis. The median duration of symptoms was 6 (1-84) months; 36% had failed other fistula surgery, 12% had a complex fistula with more than one track and 35% had some form of comorbidity. The median time to healing was 3 (1-18) months; 7.4% required further surgery, but eventually 98% had complete fistula healing. The incontinence rate decreased postoperatively to 11.6% from 19% before treatment with 17/121 with pre-existing incontinence resolved and 8/107 new cases developing.
Despite its retrospective non-comparative design, the study has demonstrated that a cutting seton is a safe, well tolerated and highly successful treatment for transsphincteric anal fistula and is followed overall by improved continence. The results compare very favourably with other techniques.
经括约肌肛瘘的治疗需要在根除疾病与保留排便控制能力之间取得平衡。挂线疗法是一种古老的治疗手段,如今许多外科医生已不再使用。我们推测这一理念仍然可靠且安全,其治疗效果优于许多近期描述的方法。
对2001年至2014年这14年间因经括约肌肛瘘接受挂线疗法治疗的患者的实时电子健康记录(单机构、单外科医生)进行回顾性分析。排除患有克罗恩病、与恶性肿瘤或既往吻合术相关的肛瘘患者,以及采用包括宽松引流挂线在内的其他方法治疗肛瘘的患者。数据收集包括人口统计学资料、疾病持续时间、治疗持续时间、治疗结果及控便能力。
总计121例患者(80例男性)纳入分析,平均年龄40.2±12.2岁(范围18 - 76岁),平均随访时间5.1±3.3(1 - 24)个月。症状的中位持续时间为6(1 - 84)个月;36%的患者其他肛瘘手术失败,12%的患者存在多条瘘管的复杂性肛瘘,35%的患者有某种形式的合并症。中位愈合时间为3(1 - 18)个月;7.4%的患者需要进一步手术,但最终98%的患者肛瘘完全愈合。失禁率从治疗前的19%降至术后的11.6%,121例中有17例既往存在的失禁问题得到解决,107例中有8例出现新的失禁病例。
尽管本研究采用回顾性非对照设计,但已证明挂线疗法是一种安全、耐受性良好且治疗经括约肌肛瘘非常成功的方法,总体上能改善控便能力。其结果与其他技术相比非常有利。